## MRK: Merck & Company, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.80 indicates fundamental undervaluation. Quality metrics strong (ROE 40%, ROA 14%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-8.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($91.39)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. WINTON GROUP Ltd Makes New $3.79 Million Investment in Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251209T141523 | Bullish | Relevance: 99%
- WINTON GROUP Ltd has made a new investment of $3.79 million in Merck & Co., Inc. (NYSE:MRK), acquiring 47,854 shares in the second quarter. Other institutional investors like DLD Asset Management, Norges Bank, and Franklin Resources also significantly increased their stakes, bringing institutional ownership to 76.07% of the company's stock. Merck recently beat earnings and revenue estimates, provided strong FY2025 guidance, and raised its quarterly dividend, while analyst sentiment remains mixed with a consensus "Hold" rating.

**2. Merck & Co., Inc. (NYSE:MRK) Stock Price Down 2% - Here's What Happened**
- Source: MarketBeat | 20251209T224024 | Neutral | Relevance: 99%
-  Merck & Co., Inc. (NYSE:MRK) shares dropped 2% during mid-day trading on Tuesday, with approximately 15.26 million shares traded. The company recently reported strong Q3 earnings, beating analyst expectations, and increased its quarterly dividend. Analyst ratings are mixed, with several firms raising price targets while others maintain a "Hold" or "Sell" rating.

**3. Jim Cramer on Merck: “The People Who Run This Company Are Not Idiots”**
- Source: Insider Monkey | 20251208T003200 | Bullish | Relevance: 99%
- Jim Cramer expressed confidence in Merck & Co., Inc. (NYSE: MRK), highlighting the company's proactive acquisitions and pipeline development in anticipation of Keytruda losing patent protection. He noted that analysts are beginning to recognize Merck's strategic preparations, with Wells Fargo upgrading the stock and projecting continued growth beyond 2031. Cramer views Merck as a cheap stock with a strong pipeline and a solid 3.4% dividend yield, making it an attractive long-term investment.

**4. Fayez Sarofim & Co Sells 296,666 Shares of Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251209T110904 | Somewhat-Bullish | Relevance: 99%
-  Fayez Sarofim & Co has reduced its stake in Merck & Co., Inc. by selling 296,666 shares, now owning 2,620,725 shares worth $207.46 million. This comes amidst other institutional investors adjusting their positions in MRK, and a recent sale by an EVP of Merck, David Michael Williams. The company also announced an increased quarterly dividend and received various analyst ratings.

**5. Axa S.A. Sells 13,668 Shares of Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251209T080900 | Somewhat-Bullish | Relevance: 99%
-  Axa S.A. has reduced its stake in Merck & Co., Inc. by 1.0%, selling 13,668 shares to now own 1,306,332 shares valued at approximately $103.4 million. Other institutional investors have both increased and decreased their positions in Merck, while EVP David Michael Williams also sold 8,614 shares. Merck recently reported strong quarterly earnings, increased its dividend, and has received varied analyst ratings with a consensus "Hold."

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Scotiabank | $120 | $105 | +14% |
| 2025-12-02 | Goldman Sachs | $120 | $92 | +30% |
| 2025-11-24 | Wells Fargo | $125 | $90 | +39% |
| 2025-11-18 | Deutsche Bank | $111 | $110 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Scotiabank | main | Sector Outperform |
| 2025-12-02 | Goldman Sachs | main | Buy |
| 2025-11-24 | Wells Fargo | up | Overweight |
| 2025-11-18 | Deutsche Bank | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.09M) |
| Sells | 2 ($1.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.2% (-0.3%)
- Blackrock Inc.: 8.7% (-1.6%)
- State Street Corpora: 4.8% (-0.3%)
- Wellington Managemen: 3.0% (-2.0%)
- JPMORGAN CHASE & CO: 2.8% (+121.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-8.5% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +21%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.80 indicates undervaluation relative to growth. Quality metrics strong (ROE 40%, ROA 14%, margin 30%). Balance sheet: $6.8B free cash flow. Analyst sentiment positive (4 raises, avg +21%). Insider selling cluster ($1.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $242.0B |
| Beta | 0.30 |
| 52W Range | $73.31 - $105.84 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.80 |
| Forward P/E | 11.0 |
| Current P/E | 10.8 |
| YoY Growth | -2.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.1% to -3.4% (-8.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.4pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.14x) but short-term weakness (below SMA20). MACD histogram bearish (-0.65), momentum weakening. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.36% (CS: 32) | Weak |
| RSI_14 | 52.1 | Neutral |
| MACD Histogram | -0.65 | Bearish |
| vs SMA20 | 0.987x | Below |
| vs SMA50 | 1.064x | Above |
| vs SMA200 | 1.141x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $96.89
- **Stop Loss:** $91.39 (5.7% risk)
- **Target:** $107.89 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 54
- **Position Value:** $5,232.06
- **Portfolio %:** 5.23%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-03 (Est: $2.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.58 | +9.9% |
| 2025Q2 | $2.03 | $2.13 | +5.0% |
| 2025Q1 | $2.14 | $2.22 | +4.0% |
| 2024Q4 | $1.67 | $1.72 | +3.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*